it is an inhibitor of idh2 it was developed by agios pharmaceuticals and is licensed to celgene for further development enasidenib is used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the idh2 gene determined by an fda approved idh2 companion diagnostic test the main serious adverse effect of enasidenib is differentiation syndrome isocitrate dehydrogenase is a critical enzyme in the citric acid cycle mutated forms of idh produce high levels of the r enantiomer of 2 hydroxyglutarate r 2 hg and can contribute to the growth of tumors idh1 catalyzes this reaction in the cytoplasm while idh2 catalyzes this reaction in mitochondria mutations of idh2 are more common than idh1 mutations 8 to 19 compared to 7 to 14 respectively in those affected with aml enasidenib disrupts this cycle by decreasing total r 2 hg levels in the mitochondria the fda granted fast track designation and orphan drug status for acute myeloid leukemia in 2014 enasidenib was approved by the fda in august 2017 for relapsed or refractory acute myeloid leukemia aml in people with specific mutations of the idh2 gene determined by an fda approved idh2 companion diagnostic test